Submitted NDA for sebetralstat as first-ever, oral on-demand treatment for HAE attacks, a pivotal moment for the HAE community
Potential FDA approval and launch of sebetralstat in first half 2025
CAMBRIDGE, Mass. & SALISBURY, England--(BUSINESS WIRE)-- KalVista Pharmaceuticals, Inc. (NASDAQ: KALV), today provided an operational update and released financial results for the fiscal year ended April 30, 2024.
“This last fiscal quarter was the most important in the history of KalVista,” said Ben Palleiko, CEO of KalVista. “Not only did we submit the NDA for sebetralstat to the FDA, but the KONFIDENT phase 3 trial results were published in The New England Journal of Medicine, supporting our view on the importance of this potential therapy. We look forward to building on these milestones as we submit additional marketing authorization applications to other national health authorities throughout 2024 and anticipate approval and launch in the US in the first half of 2025.”
Fiscal 2024 and Recent Business Highlights:
Sebetralstat
In June 2024, KalVista submitted a New Drug Application (NDA) for U.S. Food and Drug Administration (FDA) review of sebetralstat, a novel investigational oral plasma kallikrein inhibitor for the treatment of hereditary angioedema (HAE) attacks in adults and pediatric patients aged 12 years and older.
Also in June, the Company initiated ahead of schedule a pediatric clinical trial (KONFIDENT-KID) using an orally disintegrating tablet (ODT) formulation of sebetralstat designed for this population. KONFIDENT-KID will enroll approximately 24 children, with an age range of 2 to 11 years, across seven countries in North America, Europe and Asia. If approved, sebetralstat would be the first oral, on demand treatment for this population and only the second approved on-demand therapy of any type.
Data from phase 3 KONFIDENT trial of sebetralstat was published in the New England Journal of Medicine (NEJM) and presented concurrently at the European Academy of Allergy and Clinical Immunology Congress 2024 (EAACI).
Presented the U.S. subgroup analysis from the phase 3 KONFIDENT trial at the Eastern Allergy Conference (EAC) 2024, as well as the Japanese subgroup from KONFIDENT at the 123rd Annual Meeting of the Japanese Dermatological Association (JDA) 2024.
KalVista is on track for Market Authorization Application submissions to both European Medicines Agency and UK Medicines and Healthcare Products Regulatory Agency in Q3 2024 as well as a JNDA submission to the Japanese Pharmaceuticals and Medical Devices Agency in Q4 2024.
Oral Factor XIIa Inhibitor Program
The Company believes its preclinical Factor XIIa inhibitor program may have the potential to yield the first orally delivered Factor XIIa inhibitor for a variety of therapeutic indications. KalVista is undergoing a strategic review of this program to evaluate the potential for further development.
Organizational
In March 2024, KalVista announced the promotion of Benjamin L. Palleiko to Chief Executive Officer and his appointment as a member of the Board.
In February, KalVista entered into an underwriting agreement with Jefferies LLC, Leerink Partners LLC, Stifel, Nicolaus & Company, Incorporated, and Cantor Fitzgerald & Co., as the representatives of several underwriters to sell an aggregate of 7,016,312 shares of the Company’s common stock at price of $15.25 per share and pre-funded warrants to purchase up to 3,483,688 shares of common stock at a price of $15.249 per pre-funded warrant. The net proceeds from the Offering, after deducting estimated expenses, were approximately $150.1 million.
In April, William C. Fairey was appointed to the KalVista Board of Directors.
Fourth Quarter and Full Year Financial Results:
Revenue: No revenue was recognized for the three months and fiscal years ended April 30, 2024, or April 30, 2023, respectively.
R&D Expenses: Research and development expenses were $25.3 million for the three months ended April 30, 2024, compared to $24.0 million for the same period in the prior fiscal year. Research and development expenses were $86.2 million for the fiscal year ended April 30, 2024, compared to $80.3 million for the prior fiscal year. The increase in spending in the fiscal year ended April 30, 2024 primarily reflects the phase 3 KONFIDENT trial which concluded in February 2024, the ongoing KONFIDENT-S trial, and a headcount driven increase in personnel costs.
G&A Expenses: General and administrative expenses were $23.2 million for the three months ended April 30, 2024, compared to $7.8 million for the same period in the prior fiscal year. General and administrative expenses were $54.3 million for the fiscal year ended April 30, 2024, compared to $30.6 million for the prior fiscal year. The increase in G&A expenses was primarily due to increases in employee-related expenses and commercial planning expenses.
Net Loss: Net loss was $44.7 million, or $(1.02) per weighted average basic and diluted share, for the three months ended April 30, 2024, compared to net loss of $26.3 million, or $(0.77) per weighted average basic and diluted share for the same period in the prior fiscal year. Net loss was $126.6 million, or $(3.44) per weighted average basic and diluted share for the fiscal year ended April 30, 2024, compared to net loss of $92.9 million, or $(3.33) per weighted average basic and diluted share in the prior fiscal year. The increase in net loss and net loss per share primarily resulted from the increase in operating expenses, both research and development and general and administrative.
Cash position: Cash, cash equivalents and marketable securities were $210.4 million on April 30, 2024, compared to $149.4 million on April 30, 2023. The increase in the net cash and marketable securities position was primarily due to the net proceeds received from the February 2024 underwritten offering of common stock and pre-funded warrants.
About KalVista Pharmaceuticals, Inc.
KalVista Pharmaceuticals, Inc. is a global pharmaceutical company focused on the development and delivery of oral medicines for diseases with significant unmet need. KalVista announced positive phase 3 data for the KONFIDENT trial for its oral, on-demand therapy sebetralstat in February 2024 and submitted an NDA with the FDA in June 2024. KalVista expects to approval in the UK, the European Union, and Japan later in 2024.
For more information about KalVista, please visit .
Forward-Looking Statements
This press release contains "forward-looking" statements within the meaning of the safe harbor provisions of the U.S. Private Securities Litigation Reform Act of 1995. Forward-looking statements can be identified by words such as: "anticipate," "intend," "plan," "goal," "seek," "believe," "project," "estimate," "expect," "strategy," "future," "likely," "may," "should," "will" and similar references to future periods. These statements are subject to numerous risks and uncertainties that could cause actual results to differ materially from what we expect. Examples of forward-looking statements include, among others, timing or outcomes of communications with the FDA, our expectations about safety and efficacy of our product candidates and timing of clinical trials and its results, our ability to commence clinical studies or complete ongoing clinical studies, including our KONFIDENT-S and KONFIDENT-KID trials, and to obtain regulatory approvals for sebetralstat and other candidates in development, the success of any efforts to commercialize sebetralstat, the ability of sebetralstat and other candidates in development to treat HAE or other diseases, and the future progress and potential success of our oral Factor XIIa program. Further information on potential risk factors that could affect our business and financial results are detailed in our filings with the Securities and Exchange Commission, including in our annual report on Form 10-K for the year ended April 30, 2023, our quarterly reports on Form 10-Q, and our other reports that we may make from time to time with the Securities and Exchange Commission. We undertake no obligation to publicly update any forward-looking statement, whether written or oral, that may be made from time to time, whether as a result of new information, future developments or otherwise.
KalVista Pharmaceuticals Inc.
Condensed Consolidated Balance Sheets
(in thousands, except share and per share amounts)
(Unaudited)
April 30,
April 30,
2024
2023
Assets
Current assets:
Cash and cash equivalents
$
31,789
$
56,238
Marketable securities
178,612
93,137
Research and development tax credit receivable
8,439
16,568
Prepaid expenses and other current assets
6,850
6,383
Total current assets
225,690
172,326
Property and equipment, net
2,227
2,948
Right of use assets
6,920
7,822
Other assets
567
106
Total assets
$
235,404
$
183,202
Liabilities and stockholders' equity
Current liabilities:
Accounts payable
$
9,107
$
4,817
Accrued expenses
12,398
9,128
Lease liability - current portion
1,302
1,087
Total current liabilities
22,807
15,032
Long-term liabilities:
Lease liability - net of current portion
6,015
7,145
Total long-term liabilities
6,015
7,145
Stockholders’ equity:
Common stock, $0.001 par value
42
34
Additional paid-in capital
679,754
507,133
Accumulated deficit
(469,726
)
(343,082
)
Accumulated other comprehensive loss
(3,488
)
(3,060
)
Total stockholders’ equity
206,582
161,025
Total liabilities and stockholders' equity
$
235,404
$
183,202
KalVista Pharmaceuticals Inc.
Condensed Consolidated Statement of Operations
(in thousands, except share and per share amounts)
(Unaudited)
Three Months Ended
Years Ended
April 30,
April 30,
2024
2023
2024
2023
Revenue
$
—
$
—
$
—
$
—
Operating expenses:
Research and development
25,248
23,951
86,167
80,276
General and administrative
23,207
7,777
54,278
30,595
Total operating expenses
48,455
31,728
140,445
110,871
Operating loss
(48,455
)
(31,728
)
(140,445
)
(110,871
)
Other income:
Interest income
1,513
808
3,896
2,232
Foreign currency exchange rate (loss) gain
(140
)
327
138
90
Other income
2,432
4,288
9,767
15,642
Total other income
3,805
5,423
13,801
17,964
Net loss
$
(44,650
)
$
(26,305
)
$
(126,644
)
$
(92,907
)
Net loss per share, basic and diluted
$
(1.02
)
$
(0.77
)
$
(3.44
)
$
(3.33
)
Weighted average common shares outstanding, basic and diluted
43,590,657
34,342,664
36,786,575
27,890,846
KalVista Pharmaceuticals Inc.
Condensed Consolidated Statements of Cash Flows
(in thousands, unaudited)
Years Ended
April 30,
2024
2023
Cash flows from operating activities
Net loss
$
(126,644
)
$
(92,907
)
Adjustments to reconcile net loss to net cash used in operating activities:
Depreciation and amortization
816
718
Stock-based compensation expense
21,915
9,922
Realized (gain) loss from sale of marketable securities
(1,325
)
139
Non-cash operating lease expense
(12
)
84
Amortization of premium on marketable securities
92
988
Foreign currency exchange loss (gain)
760
(1,618
)
Changes in operating assets and liabilities:
Research and development tax credit receivable
8,176
(2,316
)
Prepaid expenses and other current assets
(538
)
6,690
Accounts payable
4,320
1,107
Accrued expenses
3,209
1,932
Net cash used in operating activities
(89,231
)
(75,261
)
Cash flows from investing activities
Purchases of marketable securities
(189,231
)
(98,246
)
Sales and maturities of marketable securities
104,955
140,857
Acquisition of property and equipment
(42
)
(1,196
)
Capitalized website development costs
(401
)
-
Net cash provided by investing activities
(84,719
)
41,415
Cash flows from financing activities
Issuance of common stock, net of offering expenses
106,560
56,582
Issuance of pre-funded warrants, net of offering expenses
43,508
1,085
Issuance of common stock from equity incentive plans
646
449
Net cash provided by financing activities
150,714
58,116
Effect of exchange rate changes on cash and cash equivalents
(1,213
)
1,236
Net (decrease) increase in cash and cash equivalents
(24,449
)
25,506
Cash and cash equivalents at beginning of period
56,238
30,732
Cash and cash equivalents at end of period
$
31,789
$
56,238
View source version on businesswire.com:
Contacts
KalVista Pharmaceuticals, Inc.
Jarrod Aldom
Vice President, Corporate Communications
(201) 705-0254
jarrod.aldom@kalvista.com
Ryan Baker
Head, Investor Relations
(617) 771-5001
ryan.baker@kalvista.com
Source: KalVista Pharmaceuticals, Inc.
View this news release online at:
